Fusion Antibodies PLC

Fusion Antibodies plc is a contract research organization that researches, develops, and manufactures recombinant proteins and antibodies for cancer and infectious diseases. It operates in the United Kingdom, the rest of Europe, North America, and internationally. Its services include monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation, recombinant protein expression, and stable cell line development and cGMP scale-up. The company serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies, and has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Incorporated in 2000, it is based in Belfast, the United Kingdom.